Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review.

Therapeutic advances in chronic disease

Peters J, Booth A, Peters R.
PMID: 26137206
Ther Adv Chronic Dis. 2015 Jul;6(4):160-9. doi: 10.1177/2040622315582353.

BACKGROUND: There is some evidence to suggest a possible association between calcium channel blocker (CCB) use and a lower decline in cognitive function compared with use of other hypertensive treatments. In particular, there is an emerging interest in the...

Cite
Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis. 2015;6(4):160-9doi: 10.1177/2040622315582353.
Peters, J., Booth, A., & Peters, R. (2015). Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Therapeutic advances in chronic disease, 6(4), 160-9. https://doi.org/10.1177/2040622315582353
Peters, Jean, et al. "Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review." Therapeutic advances in chronic disease vol. 6,4 (2015): 160-9. doi: https://doi.org/10.1177/2040622315582353
Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis. 2015 Jul;6(4):160-9. doi: 10.1177/2040622315582353. PMID: 26137206; PMCID: PMC4480546.
Copy Download .nbib Format: NLM
Cilazapril-induced pleural effusion: A case report and review of the literature.

Annals of thoracic medicine

Zaki SA, Nilofer AR.
PMID: 21760854
Ann Thorac Med. 2011 Jul;6(3):157-8. doi: 10.4103/1817-1737.82459.

No abstract available.

Cite
Zaki SA, Nilofer AR. Cilazapril-induced pleural effusion: A case report and review of the literature. Ann Thorac Med. 2011;6(3):157-8doi: 10.4103/1817-1737.82459.
Zaki, S. A., & Nilofer, A. R. (2011). Cilazapril-induced pleural effusion: A case report and review of the literature. Annals of thoracic medicine, 6(3), 157-8. https://doi.org/10.4103/1817-1737.82459
Zaki, Syed Ahmed, and Nilofer, Angadi Rajasab. "Cilazapril-induced pleural effusion: A case report and review of the literature." Annals of thoracic medicine vol. 6,3 (2011): 157-8. doi: https://doi.org/10.4103/1817-1737.82459
Zaki SA, Nilofer AR. Cilazapril-induced pleural effusion: A case report and review of the literature. Ann Thorac Med. 2011 Jul;6(3):157-8. doi: 10.4103/1817-1737.82459. PMID: 21760854; PMCID: PMC3131765.
Copy Download .nbib Format: NLM
Development of UV-visible spectrophotometric methods for the quantitative and .

Drug development and industrial pharmacy

Khalil A, Kashif M.
PMID: 34286656
Drug Dev Ind Pharm. 2021 Jul;47(7):1100-1111. doi: 10.1080/03639045.2021.1957918. Epub 2021 Aug 06.

For cilazapril (CLZ), analytical methods based on donor-acceptor phenomenon that are simple, rapid with broad linear dynamic range for the quantification of drug are not available in the literature. Considering the requirement for the methods, in this study, two...

Cite
Khalil A, Kashif M. Development of UV-visible spectrophotometric methods for the quantitative and . Drug Dev Ind Pharm. 2021;47(7):1100-1111doi: 10.1080/03639045.2021.1957918.
Khalil, A., & Kashif, M. (2021). Development of UV-visible spectrophotometric methods for the quantitative and . Drug development and industrial pharmacy, 47(7), 1100-1111. https://doi.org/10.1080/03639045.2021.1957918
Khalil, Adila, and Kashif, Mohammad. "Development of UV-visible spectrophotometric methods for the quantitative and ." Drug development and industrial pharmacy vol. 47,7 (2021): 1100-1111. doi: https://doi.org/10.1080/03639045.2021.1957918
Khalil A, Kashif M. Development of UV-visible spectrophotometric methods for the quantitative and . Drug Dev Ind Pharm. 2021 Jul;47(7):1100-1111. doi: 10.1080/03639045.2021.1957918. Epub 2021 Aug 06. PMID: 34286656.
Copy Download .nbib Format: NLM
Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

O'Rawe M, Wickremesekera AC, Pandey R, Young D, Sim D, FitzJohn T, Burgess C, Kaye AH, Tan ST.
PMID: 34929651
J Clin Neurosci. 2021 Dec 04;95:48-54. doi: 10.1016/j.jocn.2021.11.023. Epub 2021 Dec 04.

Glioblastoma is the most common and most aggressive primary brain cancer in adults. Standard treatment of glioblastoma consisting of maximal safe resection, adjuvant radiotherapy and chemotherapy with temozolomide, results in an overall median survival of 14.6 months. The aggressive...

Cite
O'Rawe M, Wickremesekera AC, Pandey R, et al. Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. J Clin Neurosci. 2021;95:48-54doi: 10.1016/j.jocn.2021.11.023.
O'Rawe, M., Wickremesekera, A. C., Pandey, R., Young, D., Sim, D., FitzJohn, T., Burgess, C., Kaye, A. H., & Tan, S. T. (2021). Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 9548-54. https://doi.org/10.1016/j.jocn.2021.11.023
O'Rawe, Michael, et al. "Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial." Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia vol. 95 (2021): 48-54. doi: https://doi.org/10.1016/j.jocn.2021.11.023
O'Rawe M, Wickremesekera AC, Pandey R, Young D, Sim D, FitzJohn T, Burgess C, Kaye AH, Tan ST. Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. J Clin Neurosci. 2021 Dec 04;95:48-54. doi: 10.1016/j.jocn.2021.11.023. Epub 2021 Dec 04. PMID: 34929651.
Copy Download .nbib Format: NLM
The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study.

Diabetic medicine : a journal of the British Diabetic Association

[No authors listed]
PMID: 16842490
Diabet Med. 2006 Jul;23(7):818. doi: 10.1111/j.1464-5491.2006.01969.x.

No abstract available.

Cite
The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med. 2006;23(7):818doi: 10.1111/j.1464-5491.2006.01969.x.
(2006). The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabetic medicine : a journal of the British Diabetic Association, 23(7), 818. https://doi.org/10.1111/j.1464-5491.2006.01969.x
"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study." Diabetic medicine : a journal of the British Diabetic Association vol. 23,7 (2006): 818. doi: https://doi.org/10.1111/j.1464-5491.2006.01969.x
The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med. 2006 Jul;23(7):818. doi: 10.1111/j.1464-5491.2006.01969.x. PMID: 16842490.
Copy Download .nbib Format: NLM
Cilazapril treatment in a cohort of seven patients with congestive heart failure: a seven-year follow-up study.

Current therapeutic research, clinical and experimental

Demirel S, Erk O, Unal M, Vatansever S, Oflaz H, Yücesir I, Florinalı N, Adalet K.
PMID: 24944363
Curr Ther Res Clin Exp. 2003 Mar;64(3):167-75. doi: 10.1016/S0011-393X(03)00026-2.

BACKGROUND: Although angiotensin-converting enzyme inhibitors (ACEIs) have been shown to prolong life in patients with congestive heart failure (CHF), the prognosis of these patients remains poor.OBJECTIVE: The purpose of the study was to reevaluate a cohort of patients with...

Cite
Demirel S, Erk O, Unal M, et al. Cilazapril treatment in a cohort of seven patients with congestive heart failure: a seven-year follow-up study. Curr Ther Res Clin Exp. 2003;64(3):167-75doi: 10.1016/S0011-393X(03)00026-2.
Demirel, S., Erk, O., Unal, M., Vatansever, S., Oflaz, H., Yücesir, I., Florinalı, N., & Adalet, K. (2003). Cilazapril treatment in a cohort of seven patients with congestive heart failure: a seven-year follow-up study. Current therapeutic research, clinical and experimental, 64(3), 167-75. https://doi.org/10.1016/S0011-393X(03)00026-2
Demirel, Seref, et al. "Cilazapril treatment in a cohort of seven patients with congestive heart failure: a seven-year follow-up study." Current therapeutic research, clinical and experimental vol. 64,3 (2003): 167-75. doi: https://doi.org/10.1016/S0011-393X(03)00026-2
Demirel S, Erk O, Unal M, Vatansever S, Oflaz H, Yücesir I, Florinalı N, Adalet K. Cilazapril treatment in a cohort of seven patients with congestive heart failure: a seven-year follow-up study. Curr Ther Res Clin Exp. 2003 Mar;64(3):167-75. doi: 10.1016/S0011-393X(03)00026-2. PMID: 24944363; PMCID: PMC4053039.
Copy Download .nbib Format: NLM
Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

O'Rawe M, Wickremesekera AC, Pandey R, Young D, Sim D, FitzJohn T, Burgess C, Kaye AH, Tan ST.
PMID: 34929651
J Clin Neurosci. 2021 Dec 04;95:48-54. doi: 10.1016/j.jocn.2021.11.023. Epub 2021 Dec 04.

Glioblastoma is the most common and most aggressive primary brain cancer in adults. Standard treatment of glioblastoma consisting of maximal safe resection, adjuvant radiotherapy and chemotherapy with temozolomide, results in an overall median survival of 14.6 months. The aggressive...

Cite
O'Rawe M, Wickremesekera AC, Pandey R, et al. Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. J Clin Neurosci. 2021;95:48-54doi: 10.1016/j.jocn.2021.11.023.
O'Rawe, M., Wickremesekera, A. C., Pandey, R., Young, D., Sim, D., FitzJohn, T., Burgess, C., Kaye, A. H., & Tan, S. T. (2021). Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 9548-54. https://doi.org/10.1016/j.jocn.2021.11.023
O'Rawe, Michael, et al. "Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial." Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia vol. 95 (2021): 48-54. doi: https://doi.org/10.1016/j.jocn.2021.11.023
O'Rawe M, Wickremesekera AC, Pandey R, Young D, Sim D, FitzJohn T, Burgess C, Kaye AH, Tan ST. Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. J Clin Neurosci. 2021 Dec 04;95:48-54. doi: 10.1016/j.jocn.2021.11.023. Epub 2021 Dec 04. PMID: 34929651.
Copy Download .nbib Format: NLM
Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

O'Rawe M, Wickremesekera AC, Pandey R, Young D, Sim D, FitzJohn T, Burgess C, Kaye AH, Tan ST.
PMID: 34929651
J Clin Neurosci. 2021 Dec 04;95:48-54. doi: 10.1016/j.jocn.2021.11.023. Epub 2021 Dec 04.

Glioblastoma is the most common and most aggressive primary brain cancer in adults. Standard treatment of glioblastoma consisting of maximal safe resection, adjuvant radiotherapy and chemotherapy with temozolomide, results in an overall median survival of 14.6 months. The aggressive...

Cite
O'Rawe M, Wickremesekera AC, Pandey R, et al. Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. J Clin Neurosci. 2021;95:48-54doi: 10.1016/j.jocn.2021.11.023.
O'Rawe, M., Wickremesekera, A. C., Pandey, R., Young, D., Sim, D., FitzJohn, T., Burgess, C., Kaye, A. H., & Tan, S. T. (2021). Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 9548-54. https://doi.org/10.1016/j.jocn.2021.11.023
O'Rawe, Michael, et al. "Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial." Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia vol. 95 (2021): 48-54. doi: https://doi.org/10.1016/j.jocn.2021.11.023
O'Rawe M, Wickremesekera AC, Pandey R, Young D, Sim D, FitzJohn T, Burgess C, Kaye AH, Tan ST. Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. J Clin Neurosci. 2021 Dec 04;95:48-54. doi: 10.1016/j.jocn.2021.11.023. Epub 2021 Dec 04. PMID: 34929651.
Copy Download .nbib Format: NLM
Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

O'Rawe M, Wickremesekera AC, Pandey R, Young D, Sim D, FitzJohn T, Burgess C, Kaye AH, Tan ST.
PMID: 34929651
J Clin Neurosci. 2021 Dec 04;95:48-54. doi: 10.1016/j.jocn.2021.11.023. Epub 2021 Dec 04.

Glioblastoma is the most common and most aggressive primary brain cancer in adults. Standard treatment of glioblastoma consisting of maximal safe resection, adjuvant radiotherapy and chemotherapy with temozolomide, results in an overall median survival of 14.6 months. The aggressive...

Cite
O'Rawe M, Wickremesekera AC, Pandey R, et al. Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. J Clin Neurosci. 2021;95:48-54doi: 10.1016/j.jocn.2021.11.023.
O'Rawe, M., Wickremesekera, A. C., Pandey, R., Young, D., Sim, D., FitzJohn, T., Burgess, C., Kaye, A. H., & Tan, S. T. (2021). Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 9548-54. https://doi.org/10.1016/j.jocn.2021.11.023
O'Rawe, Michael, et al. "Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial." Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia vol. 95 (2021): 48-54. doi: https://doi.org/10.1016/j.jocn.2021.11.023
O'Rawe M, Wickremesekera AC, Pandey R, Young D, Sim D, FitzJohn T, Burgess C, Kaye AH, Tan ST. Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. J Clin Neurosci. 2021 Dec 04;95:48-54. doi: 10.1016/j.jocn.2021.11.023. Epub 2021 Dec 04. PMID: 34929651.
Copy Download .nbib Format: NLM
Arterial hypertension and sleep apnoea: effect of the angiotensin-converting enzyme (ACE) inhibitor cilazapril on continuously measured blood pressure during sleep and wakefulness.

Journal of sleep research

Grote L, Heitmann J, Penzel T, Cassel W, Ploch T, Peter JH, Von Wichert P.
PMID: 10607186
J Sleep Res. 1995 Jun;4:112-116. doi: 10.1111/j.1365-2869.1995.tb00199.x.

Male patients with arterial hypertension and obstructive sleep-related breathing disorders (mean age 50 y, Body Mass Index (BMI) 32.4 kg m-2, Respiratory Disturbance Index (RDI) 47.2 and systolic/diastolic blood pressure (SBD/DBD) 162/103 mmHg) were examined before and after 8...

Cite
Grote L, Heitmann J, Penzel T, et al. Arterial hypertension and sleep apnoea: effect of the angiotensin-converting enzyme (ACE) inhibitor cilazapril on continuously measured blood pressure during sleep and wakefulness. J Sleep Res. 1995;4:112-116doi: 10.1111/j.1365-2869.1995.tb00199.x.
Grote, L., Heitmann, J., Penzel, T., Cassel, W., Ploch, T., Peter, J. H., & Von Wichert P. (1995). Arterial hypertension and sleep apnoea: effect of the angiotensin-converting enzyme (ACE) inhibitor cilazapril on continuously measured blood pressure during sleep and wakefulness. Journal of sleep research, 4112-116. https://doi.org/10.1111/j.1365-2869.1995.tb00199.x
Grote, et al. "Arterial hypertension and sleep apnoea: effect of the angiotensin-converting enzyme (ACE) inhibitor cilazapril on continuously measured blood pressure during sleep and wakefulness." Journal of sleep research vol. 4 (1995): 112-116. doi: https://doi.org/10.1111/j.1365-2869.1995.tb00199.x
Grote L, Heitmann J, Penzel T, Cassel W, Ploch T, Peter JH, Von Wichert P. Arterial hypertension and sleep apnoea: effect of the angiotensin-converting enzyme (ACE) inhibitor cilazapril on continuously measured blood pressure during sleep and wakefulness. J Sleep Res. 1995 Jun;4:112-116. doi: 10.1111/j.1365-2869.1995.tb00199.x. PMID: 10607186.
Copy Download .nbib Format: NLM
A liquid chromatography/positive ion tandem mass spectrometry method for the determination of cilazapril and cilazaprilat in human plasma.

Talanta

Lee HW, Park WS, Cho SH, Kim MH, Seo JH, Kim YW, Kim SS, Lee YS, Lee KT.
PMID: 19071268
Talanta. 2007 Jan 15;71(1):62-7. doi: 10.1016/j.talanta.2006.03.020. Epub 2006 Mar 31.

A simple, rapid, and sensitive high-performance liquid chromatography (HPLC)-electrospray ionization (ESI) tandem mass spectrometric method (LC-MS/MS) has been developed for simultaneous determination of cilazapril levels and its active metabolite, cilazaprilat, in human plasma using enalapril as internal standard. The...

Cite
Lee HW, Park WS, Cho SH, et al. A liquid chromatography/positive ion tandem mass spectrometry method for the determination of cilazapril and cilazaprilat in human plasma. Talanta. 2006;71(1):62-7doi: 10.1016/j.talanta.2006.03.020.
Lee, H. W., Park, W. S., Cho, S. H., Kim, M. H., Seo, J. H., Kim, Y. W., Kim, S. S., Lee, Y. S., & Lee, K. T. (2007). A liquid chromatography/positive ion tandem mass spectrometry method for the determination of cilazapril and cilazaprilat in human plasma. Talanta, 71(1), 62-7. https://doi.org/10.1016/j.talanta.2006.03.020
Lee, Heon-Woo, et al. "A liquid chromatography/positive ion tandem mass spectrometry method for the determination of cilazapril and cilazaprilat in human plasma." Talanta vol. 71,1 (2007): 62-7. doi: https://doi.org/10.1016/j.talanta.2006.03.020
Lee HW, Park WS, Cho SH, Kim MH, Seo JH, Kim YW, Kim SS, Lee YS, Lee KT. A liquid chromatography/positive ion tandem mass spectrometry method for the determination of cilazapril and cilazaprilat in human plasma. Talanta. 2007 Jan 15;71(1):62-7. doi: 10.1016/j.talanta.2006.03.020. Epub 2006 Mar 31. PMID: 19071268.
Copy Download .nbib Format: NLM
Thermal analysis study of antihypertensive drugs telmisartan and cilazapril.

Advanced pharmaceutical bulletin

Saber RA, Attia AK, Salem WM.
PMID: 24754013
Adv Pharm Bull. 2014;4(3):283-7. doi: 10.5681/apb.2014.041. Epub 2014 Feb 07.

PURPOSE: The aim of the present work is to study the thermal analysis of telmisartan and cilazapril.METHODS: Thermogravimetry (TGA), derivative thermogravimetry (DTG) and differential thermal analysis (DTA) were used through the work to achieve the thermal analysis study of...

Cite
Saber RA, Attia AK, Salem WM. Thermal analysis study of antihypertensive drugs telmisartan and cilazapril. Adv Pharm Bull. 2014;4(3):283-7doi: 10.5681/apb.2014.041.
Saber, R. A., Attia, A. K., & Salem, W. M. (2014). Thermal analysis study of antihypertensive drugs telmisartan and cilazapril. Advanced pharmaceutical bulletin, 4(3), 283-7. https://doi.org/10.5681/apb.2014.041
Saber, Refaat Ahmed, et al. "Thermal analysis study of antihypertensive drugs telmisartan and cilazapril." Advanced pharmaceutical bulletin vol. 4,3 (2014): 283-7. doi: https://doi.org/10.5681/apb.2014.041
Saber RA, Attia AK, Salem WM. Thermal analysis study of antihypertensive drugs telmisartan and cilazapril. Adv Pharm Bull. 2014;4(3):283-7. doi: 10.5681/apb.2014.041. Epub 2014 Feb 07. PMID: 24754013; PMCID: PMC3992965.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries